FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer

The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.

Source: CancerNetwork - October 17, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news